"Historically speaking there appears to be a very slow take up in many of their clinical trials with participants always on the minimal side, despite the large number of sites in play. The FDA allows Imugene to recruit between 3 - 6 patients per cohort in some of their trials, only to find its always closer to 3 enrolled. We only now hear as at May 2023 of one patient enrolled in the much lauded OASIS Trial for solid tumours when close to 90 percent of all cancer patients suffer with solid tumour diagnosis. "
Comment :
I think the ting to remember with these trials ....is getting the right number of applicants is not always easy .
OK they could just say ..." anyone who is about to die from some sort of cancer ...line up and have a crack at this " ...and they would most likely fill the MCG with applicants .
But as you and most others know ...it doesn't work like this .
They need to filter right down to "specific criteria " ....to fulfill the design set up of the trial ( as might be required to get a set of data to support the hypothesis or proof of concept )
DT Shares posted a great post the other day showing the specific design and requirement of the required candidates ..... if you think about ALL the boxes that need to be ticked ....what might have started with 2000 applicants ....quickly gets cut by 90% ....and than maybe by another 90% etc etc
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
Check out the Criteria - INCLUSIONS
Exclusions
Getting the right data is critical .... so its easy to see how timelines can blow out
Then again this could simply be a case of IMU being unrealistic in defining their commercial timelines ....... as well as holders being a bit un realistic in their expectations .
Longer term ....it doesn't change the potential value proposition if the science is right .
IMU Price at posting:
8.7¢ Sentiment: Buy Disclosure: Held
(20min delay)
